AstraZeneca Pharmaceuticals LP
NEWS
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 22, 2021.
This program limits the prices drug manufacturers can charge for therapies sold to specific healthcare facilities, including public hospitals and community health centers.
The new findings likely throw a wrench in the company’s plans to deliver millions of much-needed vaccine doses to the European Union soon.
A recent study conducted by Public Health England found that the available vaccines were “highly effective” at preventing hospitalization after two doses.
The failure marks a setback in the hunt for means other than vaccines to provide protection against the novel coronavirus and its variants.
The EMA identified a rare blood condition, capillary leak syndrome, as a potential side effect of AstraZeneca’s Vaxzevria.
Although the COVID-19 pandemic is waning in the U.S., there is still plenty of research and news about the disease. Here’s a look.
After three years, 85.9% of patients treated post-surgically with Lynparza were free of invasive breast cancer and second cancers compared to 77.1% of the placebo group.
JOBS
IN THE PRESS